Several studies have shown an increased breast cancer specific mortality in patients with metabolic syndrome, likely due to crosstalk between the insulin-like growth factor (IGF) family and signaling pathways that drive tumorigenesis, including the PI3K/AKT/mTOR pathway [17,18]. Here, MTOR is linked to metabolic syndrome.